On the mode of action of L-deprenyl in the human central nervous system. 1978

P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann

UI MeSH Term Description Entries
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
January 1978, Neuropsychobiology,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
October 1945, Physiological reviews,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
January 1976, Acta medica Scandinavica. Supplementum,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
April 1968, Archives internationales de pharmacodynamie et de therapie,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
March 1957, Fiziologicheskii zhurnal SSSR imeni I. M. Sechenova,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
January 1967, Acta medica Scandinavica. Supplementum,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
May 1937, British medical journal,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
January 1966, Problemes actuels d'endocrinologie et de nutrition,
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
October 1973, Polski tygodnik lekarski (Warsaw, Poland : 1960),
P Riederer, and M B Youdim, and W D Rausch, and W Birkmayer, and K Jellinger, and D Seemann
April 1957, Bollettino della Societa italiana di biologia sperimentale,
Copied contents to your clipboard!